Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NADH:ubiquinone oxidoreductase subunit B4 pseudogene 9 (NDUFB4P9) is a **pseudogene**—a segment of DNA that closely resembles a functional gene but has lost its ability to encode a functional protein due to accumulated mutations or lack of regulatory elements[1][5]. Pseudogenes like NDUFB4P9 typically result from gene duplication or retrotransposition events and do not produce active proteins. While once considered “junk DNA,” research has shown that some pseudogenes may have regulatory roles, such as producing non-coding RNAs that can affect the expression of other genes, or serving as decoys for microRNAs[3][5]. However, there is no evidence that NDUFB4P9 functions as a therapeutic target, receptor, enzyme, transporter, or is associated with any drugs or direct disease role[1]. Its classification as a pseudogene makes it generally irrelevant for drug targeting or biomarker use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NADH:ubiquinone oxidoreductase subunit B4 pseudogene 9 (NDUFB4P9).